|
|
|
|
|
Abilify: profile and news
LOSS OF BOWEL CONTROL IS OFTEN TREATABLE Mar 1, 2006 Loss of bowel control is distressing, but treatable Mar 1, 2006 Celebrex Gets Passing Grades for Gastric and Cardiac Safety Feb 23, 2006 Recordati: 2005 Accounts Approved by the Board. Dividend ... Mar 2, 2006 Ease joint pain without blockbuster drugs Feb 28, 2006 A Joint Effort Feb 14, 2006 Popular diet aids don't ease arthritis, study suggests Feb 22, 2006 Pain relief: Finding the right drug Feb 9, 2006 Superbowl ads bring on the PAIN - planetc1.com-news@8:29 pm PST Feb 6, 2006 Pain relief: Finding the right drug 09 Feb 2006 Superbowl ads bring on the PAIN - planetc1.com-news@8:29 pm PST Feb 6, 2006 News and views Jan 10, 2006 Back pain relief may be within your reach Jan 15, 2006 Update 10: Cheney Hospitalized, Then Released Jan 9, 2006 Cough Medicine Doesn't Work, May Harm Kids Jan 9, 2006 ACCP: No evidence shows cough syrups work for coughs Jan 10, 2006 OTC cough remedies do not work as expected Jan 10, 2006 Fraudulent Painkiller Study Leaves Scientists In Lurch Jan 18, 2006 Jojo is home freeCourt acquits Palaver editor Jan 19, 2006 No evidence that COX-2 inhibitors provide greater gastroprotection Dec 9, 2005 Pain relievers don’t increase risk of heart attack — Study Dec 5, 2005 New England Journal Charges Merck Deleted Vioxx Study Data Dec 8, 2005 Three myocardial infarctions with Vioxx were not included in VIGOR ... Dec 9, 2005 Ibuprofen, Naproxen: No Heart Risk Nov 28, 2005 Long-Term Use of Ibuprofen and Naproxen Do Not Increase Heart ... Nov 30, 2005 GLENN ELLIS' STRATEGIES FOR WELL BEING: Gout Nov 17, 2005 Most Recent Vioxx Study Shows Merck Will Need More Than Courtroom ... Nov 14, 2005 Understanding Common Pain Killers Oct 8, 2005 Roche Ireland to cut jobs as profits dive Sep 18, 2005 Cyclist needs to improve flexibility Sep 20, 2005 What Ails You by Jackie Randa Sep 20, 2005 Even if you wash hands, restroom germs still lurk Sep 19, 2005 Sleep deprivation makes driving dangerous Sep 18, 2005 2nd suit in fatal crash brings total sought to $12 million Sep 20, 2005 Boat driver may face stiffer charges Sep 19, 2005 How to choose the right over-the-counter medication for you Sep 11, 2005 Other information Indication For the treatment of schizophrenia Pharmacology Aripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Mechanism Of Action Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5- HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors and moderate affinity for the serotonin reuptake pump. Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors. Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptor. Drug Category Antipsychotics; ATC:N05AX12 Brand Names/Synonyms Abilify; Abilitat; Aripiprazole; Aripiprazole [Usan]; OPC 31 Dosage Forms Not Available Absorption Not Available Interactions -->Interactions for Aripiprazole: Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol. Due to its α1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; weaker inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced. No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions). Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro. Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY. -->Chemical IUPAC Name 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one Chemical Formula C23H27Cl2N3O2 Half Life 75-146 hours Drug Type Approved Drug # Accession No APRD00638 CAS Registry Number 129722-12-9 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |